Endothelin-1 (ET-1), a potent vasoconstrictor, and parathyroid hormone-related protein (PTH-rP), a potent vasorelaxant, are present and synthesized in human endometrium. The production of these vasoactive peptides in stromal cells of the human endometrium is modulated by sex steroid hormones. In addition, neutral endopeptidase 24.11 (also called enkephalinase), which degrades ET-1, is expressed in the stromal cells of the endometrium, and the levels of this enzyme (mRNA, protein and specific activity) are increased in response to progesterone/progestin. The sex steroid hormone-mediated regulation of vasoactive peptide formation and action in the human endometrium is believed to serve a key role in modulating spiral artery tone/blood flow, and thus endometrial bleeding, whether progestin induced or naturally occurring. Moreover, the expression of ET-1, PTH-rP and enkephalinase is modulated by transforming growth factor-p". We hypothesize that the inappropriate expression of ET-1, enkephalinase and PTH-rP in endometrial stromal cells during synthetic progestin administration may be one cause of abnormal endometrial development and erratic endometrial bleeding.
Introduction
Sex steroid hormone regulation of the formation of vasoactive peptides in endometrial stromal cells must be considered in ascertaining the cause and means of eliminating aberrant endometrial bleeding, whether progestin induced or naturally occurring. The proximal cause of progestin-induced erratic or excessive uterine bleeding may be attributable to abnormal endometrial angiogenesis, interrupted vascular endothelial cell integrity/function or the anomalous growth of endometrial tissue. We hypothesize that the malapropos or inopportune production of vasoactive peptides in endometrial stromal cells during synthetic progestin administration, causing untimely modifications in spiral artery vascular tone/blood flow, may be one determinant of abnormal endometrial development and, thus, erratic endometrial bleeding. Until recently, little was known of a paracrine (i.e. local biochemical) arrangement in endometrium that regulates vascular (spiral artery) tone or blood flow, the endocrine regulation of this system, or its function in limiting blood loss with normal menstruation. Several recent discoveries have provided insights into the nature of the components of this putative arrangement, which we refer to as the 'endometrial stromal cell vasoactive peptide system'. Vasoactive peptides are synthesized in the stromal cells of the endometrium in a sex steroid hormone-dependent fashion. These peptides may act in a paracrine manner via the adventitial surface of the spiral arteries/arterioles to promulgate the changes in vessel tone that accompany the vascular changes of the endometrium of normal but non-fertile ovarian cycles.
We have proposed that the changes in vessel tone accompanying these vascular transformations are mediated by sex steroid hormone-responsive, endometrial stromal cell-derived, vasoactive peptides. Parathyroid hormone-related protein (PTHrP; a vasorelaxant) and endothelin-1 (ET-1; a vasocontractant) are synthesized in the stromal cells of the human endometrium Economos et al, 1992) . The rate of formation of these vasoactive peptides is modulated by oestradiol-17P , progesterone and transforming growth factors-p (TGFPl, TGF-P2 and TGF-P3) Economos et al, 1992) . The tissue levels of ET-1 may also be regulated by enzymatic degradation in a reaction catalysed by enkephalinase, a plasma membrane ectoenzyme that is localized in the stromal cells. The specific activity of endometrial enkephalinase increases in response to progesterone in vivo and medroxyprogesterone acetate (MPA) in vitro (Casey et al, 1991) . The endometrial stromal cell vasoactive peptide system may also be modulated by locally produced TGF-P which, in vitro, acts to increase the levels of PTHrP and ET-1 mRNA by ~10-and 3-fold respectively Economos et al., 1992) and to decrease (by 80%) the specific activity of enkephalinase . In vitro, TGF-P acts on stromal cells to complement selected actions of MPA that facilitate decidualization. However, TGF-P 1 also acts as a highly selective, gene-specific antiprogestin to attenuate the effect of MPA on some genes, e.g. PTH-rP, ET-1 and enkephalinase MacDonald, 1993b, 1994) . This restrictive and specific antiprogestin action of TGF-P 1, together with progesterone withdrawal, should promote increased levels of ET-1 at the spiral artery-stromal cell interface. Some synthetic progestins act to perturb this system directly by modifying the expression of the PTHrP gene, the preproET-1 gene and the enkephalinase gene, and indirectly by modifying (i) cellular responses to oestrogen, (ii) the expression of TGF-P genes or (iii) the conversion of latent to active TGF-p.
We hypothesize that synthetic progestins may lead to anomalous tissue levels of PTH-rP, ET-1
TGF-P modulation of the endometrial ET-1-PTH-rP system
and TGF-P, inappropriate vascular perfusion and aberrant endometrial growth/development, thus causing problematic endometrial bleeding.
Cyclical changes in spiral artery blood flow
Much of our current knowledge of the cyclical modifications of the spiral arteries is attributable to research conducted >50 years ago by Professor J.Eldridge Markee (1940) . His incredible study of changes in endometrial spiral arteries will stand forever as a classic in the annals of reproductive biology research. Using a cleverly conceived experimental model, Markee (1940) was able to observe directly the sequential changes in endometrial tissues and blood vessels that faithfully evolve before each menstruation. These observations were possible because Markee (1940) perfected a technique of transplanting endometrial tissue fragments to the anterior chamber of the eye of rhesus monkeys. At magnifications of up to X150 he studied between two and 72 menstrual cycles in endometrial tissue transplants in each of 41 monkeys. During a 9 year investigation, Markee observed 432 endometrial cycles; in one monkey he examined each monthly menstruation by direct vision for 6.5 years! From these detailed observations, Markee (1940) deduced that the cyclical changes in endometrial morphology were attributable to growth cycles. He concluded that menstruation occurred during the period of regression in endometrial growth as oestrogen and progesterone secretion by the corpus luteum declined. Markee (1940) noted that during the phase of endometrial growth, the spiral arteries lengthened to an extent that was appreciably greater than was the expansion of endometrial tissue volume. The discordance in growth between spiral arteries and endometrial tissue caused even greater coiling of the spiralling vessels. It is reasonable to presume that during this time of rapid endometrial growth, blood flow is maintained in the increasingly coiled spiral arteries by locally produced vasorelaxants. It also follows that the local formation of vasoconstrictors at this time is suppressed, either directly or indirectly, by the action of sex steroid hormones secreted by the ovary. The vasorelaxant PTH-rP is produced in endometrial stromal cells, and the rate of secretion of PTH-rP by these cells is increased by oestradiol-17p (Casey etal., 1993a) . This vasorelaxant may facilitate maintenance of the high rate of blood flow in the coiled spiral arteries during the time of maximal endometrial growth and development that precedes the time of blastocyst implantation.
Spiral artery growth and vasorelaxation

Stasis in the spiral arteries: a process that causes endometrial hypoxia
After the mid-luteal phase of the ovarian cycle, as steroid secretion by the corpus luteum declines, extreme coiling of the spiral arteries occurs. The more severe twisting of the spiral arteries that ensues happens because of a reduction in endometrial tissue volume without a comparable reduction in spiral artery length. Markee (1940) observed that the reduction in endometrial tissue volume began 2-5 days before the onset of menstrual bleeding and continued during menstruation. He emphasized that the coiling of the spiral arteries at this time became so formidable and the resistance to blood flow so severe that he could count the red blood cells as they moved slowly through the hypercoiled vessels. As a consequence, endometrial hypoxia became severe and vasodilatation often occurred (45% of cycles). Markee (1940) observed that blood is supplied to the endometrium by two types of vessel: the 'straight' arteries supply the basal one-third, and the spiral arteries supply the superficial two-thirds of this tissue. Some time after the development of endometrial hypoxia, viz. between 24 and 4 h before bleeding into the endometrium commenced, there was, invariably, a period of intense vasoconstriction of the spiral arteries. The 'straight' arteries did not undergo vasospasm, but the premenstrual vasospasm of the spiral arteries was so intense that the bloodless, anaemic appearance of the functional zone of the endometrium that developed was astounding. This prompted Markee (1940) to emphasize that 'the period of vasoconstriction preceding menstruation is the most striking and constant event of the menstrual cycle'. Markee (1940) hypothesized that a 'substance' produced in endometrium during the period of vascular stasis-induced hypoxia promoted the intense premenstrual/menstrual vasoconstriction of the spiral arteries. Indeed, Markee (1940) envisaged an endometrial paracrine system long before paracrine was a 'buzz word' in endocrine parlance. He speculated that after a period of endometrial hypoxia, a vasoconstrictor was produced by the predecidualized endometrial stromal cells that lie immediately adjacent to the adventitial surface of the spiral arteries. More than 50 years later, several groups of investigators, including ourselves, have suggested that the vasoconstrictor of the spiral arteries, which serves as an endometrial tourniquet to limit menstrual blood loss, is ET-1 MacDonald, 1990, 1993a; Casey et al, 1991; Economos et al, 1992) .
Vasospasm of the spiral arteries: a process that limits blood loss with menstruation
Before the discovery of ET-1, several researchers suggested that prostaglandin (PG) F^ was the vasocontractant of the spiral arteries (Abel, 1985) . Indeed, we and others were prompted to investigate the regulation of PGFTQ and PGE2 production and metabolism (Casey et al, 1980 (Casey et al, , 1985 Gal et al, 1982; Korte et al., 1983) by endometrial stromal and epithelial cells. Today, however, it seems unlikely that PCF^ is the vasoconstrictor of the spiral arteries. It is known, for example, that indomethacin treatment of women to inhibit PG synthesis does not cause an increase in menstrual blood loss or any appreciable change in the histology of the endometrium (Landren et al, 1985; Makarainen and Ylikorkala, 1992) . Actually, the evidence available is more consistent with the likelihood that PGE2, produced in response to tissue hypoxia, contributes to the vasodilatation of the spiral arteries that Markee (1940) often observed during endometrial ischaemia. The proposal that ET-1 is the spiral artery vasoconstrictor of menstruation is consistent with Markee's findings. We have demonstrated, by in-vivo and in-vitro studies, that both the formation and degradation of ET-1 in endometrium are hormonally regulated: progesterone affects ET-1 expression, while progesterone withdrawal and TGF-pl action promote increased ET-1 synthesis and decreased ET-1 degradation (Casey et al., 1991; Economos et al, 1992; Based on the sequence of vascular changes he observed, Markee (1940) reasoned that the stasis in blood flow through the spiral arteries was the cause of endometrial ischaemia and tissue degeneration. The intense vasoconstriction of the spiral arteries comes after the period of vascular stasis and tissue hypoxia and serves to limit blood loss during menstruation. Markee's many observations and astute deductions (and the concepts that have evolved from them) stand as important cornerstones in our understanding of cyclical endometrial vascular changes. It is clear that the prodigious modifications in the spiral arteries of the endometrium that characterize the normal ovulatory (non-fertile) cycle must be regulated in a local, tissue-specific manner. Endometrium is the single tissue of adult humans that grows at an extraordinarily rapid rate in response to steroid hormones, is targeted for necrosis through hypoxia and is shed thereafter with haemorrhage at predictable, cyclical intervals. This points to an endocrineregulated, paracrine-mediated process. Thus, it was straightforward to deduce that vasoactive peptides could be generated in cells immediately adjacent to the spiral arteries, i.e. the endometrial stromal cells, in response to sex steroid hormones, and that these vasoactive peptides are available to act via the adventitial surface of endometrial vessels.
The endometrial stromal cell vasoactive peptide system
We suggest that there are three primary components of the endometrial stromal cell vasoactive peptide system: (i) PTH-rP, (ii) ET-1 and (iii) enkephalinase. Each is regulated by TGF-p1. We suggest that TGF-P 1 is a key regulator of spiral artery tone and endometrial function by its regulation of the expression and metabolism of ET-1 and PTH-rP. Moreover, we find that TGF-P and MPA act in opposing ways to modulate the expression of each of these genes. We summarize evidence that the three components of the endometrial stromal cell vasoactive peptide system are regulated by sex steroid hormones and by TGF-P, as well as evidence that TGF-P is produced and activated in endometrium.
Parathyroid hormone-related protein PTH-rP was identified in a search for the 'humoral hypercalcaemia of malignancy factor', which was believed to be produced by a number of neoplastic cells to cause a syndrome similar to hyperparathyroidism in persons with selected tumours (Martin et al., 1989) . PTH-rP (141 amino acids), like PTH (84 amino acids), is a vasorelaxant and a potent stimulus of adenylate cyclase, acting via the PTH/PTH-rP receptor (Mok et al, 1989) . PTHrP shares little homology with PTH; indeed, the amino acid homology is limited to eight of the first 13 N-terminal amino acids of the two peptides. However, binding of PTH and PTH-rP to the PTH receptor is defined by die first 27 amino acids; therefore it is reasoned that the similarity in action of the two peptides is attributable to binding to the PTH-rP/PTH receptor (Martin et al, 1989; Mok et al., 1989) .
Soon after the identification of PTH-rP as a product of neoplastic cells, it was discovered that this vasoactive peptide is also produced in many normal, non-malignant tissues. PTH-rP, unlike PTH, is normally produced and acts in a paracrine rather man an endocrine manner. Moreover, little of the PTH-rP formed in non-neoplastic tissues enters blood as intact PTH-rP (Martin et al, 1989) . Among all human tissues, those of reproduction [placenta, amnion, chorion laeve, umbilical cord, decidua, endometrium, myometrium, ovarian follicle (granulosa cells), uterine cervix and lactating mammary tissue] are especially prominent in the capacity for PTH-rP synthesis (Thiede and Rodan, 1988; Casey et al., 1992; Ferguson et al, 1992; Germain et al, 1992; Hellman et al, 1992; Gutmann etal., 1993) . Thiede et al. (1990 Thiede et al. ( , 1991a found that the PTH-rP gene is expressed in rat myometrium. They also demonstrated a rapid increase in the level of PTH-rP mRNA in myometrium of non-pregnant rats after the in-vivo administration of oestrogen. However, the highest level of PTH-rP mRNA in rat myometrium was present during pregnancy at the end of gestation and during parturition. A persistent or greater level of PTHrP mRNA was observed in pregnant rats in which parturition was delayed by the administration of progesterone; however, oophorectomy of pregnant rats late in gestation did not affect the level of PTH-rP mRNA. Uterine occupancy (by fetuses) was associated with a much greater level of PTHrP mRNA than that found in the uteri of oestrogentreated non-pregnant rats or in the unoccupied uterine homs of pregnant rats; this was probably a consequence of uterine expansion (stretch). The level of PTH-rP mRNA and PTH-rP synthesis in the wall of hollow viscera (e.g. uterus, avian oviduct, urinary bladder) increase in response to stretching (Daifotis et ai, 1992; Yamamoto et ai, 1992) ; this increase is correlated with an increase in blood flow during expansion (Thiede et ai, 1991b) .
PTH-rP is also produced in selected fetal tissues, viz. placenta, fetal kidney and parathyroid glands (Rodda et ai, 1988) . Indeed, it has been proposed that PTH-rP is the parathyroid hormone of the human fetus. Whereas PTH-rP is believed to function through the PTH/PTH-rP receptor, there are, nonetheless, unique functions for intact PTHrP (1 _ 141 ) that are not shared by intact PTH^^). Importantly, the promotion of Ca 2+ movement across the trophoblast is one of these (Abbas et ai, 1989) , suggesting that PTH-rP produced in decidual cells may facilitate Ca 2+ transport to the fetus.
Regulation of PTH-rP expression in human
endometrium by sex steroids PTH-rP mRNA is readily identified by Northern analyses in proliferative and secretory phase human endometrial tissues (Casey et ai, 1992) , and PTHrP protein is identified by immunohistochemical localization. In human endometrial stromal cells in monolayer culture maintained in serum-free medium, oestradiol (10"" 8 M) increased and MPA (10-7 M) decreased the levels of PTH-rP mRNA in a time-dependent manner (Casey et ai, 1993a) . The accumulation of immunoreactive (ir)PTH-rP in the medium of oestradiol-treated endometrial stromal cells was also increased (Casey et ai, 1993a) .
Regulation of PTH-rP gene expression in endometrial stromal cells by TGF-fi
The level of PTH-rP mRNA in stromal cells is increased markedly by TGF-P 1 (1 ng/ml); a slight increase in the levels of PTH-rP mRNA was detected after 2-4 h of TGF-P 1 treatment, and maxima] levels were attained after 8-24 h of treatment (Casey et ai, 1992) . The amount of immunoreactive and bioactive PTH-rP secreted into the medium of stromal cells also increased in a time-and dose-dependent manner in response to TGF-Pl . The accumulation of irPTH-rP in the medium of stromal cells treated with TGF-pi (1 ng/ml) was maximal by -12 h (Casey et ai, 1992) .
PTH-rP bioactivity
The bioactivity of the irPTH-rP produced by endometrial stromal cells was assessed using a bioassay specific for PTH/PTH-rP, viz. activation of adenylate cyclase in UMR-106 cells (Casey et ai, 1992 (Casey et ai, , 1994 . Conditioned medium from endometrial stromal cells treated with TGF-p i (1 ng/ml) for 24 h was more effective in stimulating cAMP production by UMR-106 cells than was conditioned medium from non-treated cells. TGF-p i did not stimulate cAMP production by UMR-106 cells, and PTH-rP (immunoreactive or bioactive) was not produced by TGF-Pl-treated human sex skin fibroblasts or MCF-7 breast cancer cells. MPA (1-100 nM) treatment of stromal cells (in serum-free medium) caused a decrease in the level of PTHrP mRNA (Casey et ai, 1993a) . Therefore, the PTH-rP gene is regulated in opposite ways by MPA and TGF-p. TGF-p acts as an antiprogestin to overcome the inhibitory effect of MPA on PTHrP gene expression. There is considerable evidence to back the belief that TGF-P, oestradiol, progesterone and synthetic progestins may regulate PTH-rP synthesis in endometrial stromal cells and PTH-rP action in spiral arteries/arterioles.
Endothetin-1
ET-1, a 21 amino acid peptide, acts via specific membrane receptors (ET A and ET B ) to mobilize Ca 2+ from extra-and intracellular sites. PreproET-1 mRNA encodes a 212 amino acid precursor at Pennsylvania State University on February 23, 2013 http://humrep.oxfordjournals.org/ Downloaded from TGF-f} modulatioii of the endometrial ET-l-PTH-rP system (Yanagisawa and Masaki, 1989) , which is processed to bigET-1 (38 amino acids), the inactive immediate precursor of ET-1. Both ET-1 and bigET-1, but not preproET-1, are secreted by cells. The conversion of bigET-1 to ET-1 can be catalysed by several non-specific proteolytic enzymes (Matsumura et al, 1990) , as well as specific intracellular and extrinsic ET-converting enzymes (Opgenorth et al., 1992; Xu et al., 1994; Emoto and Yanagisawa, 1995) . From studies conducted in vivo and in vitro, many biological effects of ET-1 have been identified, the most prominent of which is the induction of smooth muscle contraction in multiple tissues, including human vascular and uterine smooth muscle; to date, a clear-cut role for ET-1 in a physiological process has not been established.
It seems unlikely now that blood-borne ET-1 is a physiologically important vasoconstrictor. In fact, the vasoconstrictive effects of i.v. administered ET-1 are limited. For example, in a number of systems studied in vitro, the application of ET-1 to the luminal surface of vessels (in which the endothelium is intact) does not lead to contraction (deNucci et al, 1988; Pohl and Busse, 1989; Shigeno et al., 1989) . This result is explained as follows. ET-1, acting via the intraluminal surface of blood vessels, promotes the synthesis of nitric oxide (endothelium-derived relaxing factor) and prostacyclin (deNucci et al, 1988) , viz. vasorelaxants that attenuate the vasoconstrictor effect of ET-1. It is believed that ET-1, secreted by the basal surface of endothelial cells (Wagner et al., 1992) , may modulate vascular tone through an endothelial cell-smooth muscle paracrine system. In the development of the underlying hypothesis of this research, the potency of ET-1 as a vasocontractant when applied to the adventitial surface of blood vessels was an important consideration (Pohl and Busse, 1989; Shigeno et al., 1989) . This gave rise to interesting possibilities for the function of ET-1 in reproductive processes. The most obvious of these possibilities was that ET-1 modulates vascular tone in the spiral arteries of the endometrium (Casey et al, 1991; Economos et al., 1992; .
ET-1 gene expression and regulation in human endometrium There were three separate considerations that prompted our initial inquiry into the possibility that ET-1 was produced in non-endothelial cells, namely the stromal cells, of the human endometrium: (i) if ET-1 acts as a vasoconstrictor in physiological processes, it is probable that this action is mediated by way of a paracrine system in which ET-1 (secreted from mesenchymal cells) acts via the adventitial surface of contiguous vessels, e.g. the endometrial spiral arteries; (ii) there is considerable evidence against the proposition that PGF^ is the premenstrual/menstrual vasoconstrictor of endometrial spiral arteries; and (iii) if ET-1 was the paracrine-acting vasoconstrictor of spiral arteries, the levels of ET-1 in endometrium could be modulated by endocrine-regulated, paracrine-mediated mechanisms that would affect the biosynthesis/processing of bigET-1/ET-l and by modifications in the rate of ET-1 degradation. On the one hand, low levels of ET-1 at the interface of the adventitial surface of the spiral arteries with the endometrial stromal cells should favour optimal endometrial blood flow and thereby facilitate endometrial growth prior to implantation of the blastocyst. On the other hand, however, high levels of ET-1, effected by increased synthesis and diminished degradation of this vasoconstrictor, should promote the intense vasospasm of the spiral arteries such as that characteristic of the immediate premenstrual and menstrual phase of the cycle.
The levels of preproET-1 mRNA were assessed by Northern analyses of total RN A from endometrial tissue samples obtained at various times of the ovarian cycle from ovulatory women (Economos et al., 1992) . The levels of preproET-1 mRNA in premenstrual/menstrual tissues (days 26-28 and 1-5) were somewhat greater than those in proliferative (days 9-13) and secretory (days 15-25) endometria (Economos et al, 1992) . Although this difference is not marked, the finding is supportive of the proposition that ET-1 is produced in increased amounts during the premenstrual/menstrual phase of the cycle. The level of preproET-1 mRNA in freshly separated endometrial glands was somewhat greater than that in stromal cells (Economos et al., 1992) .
By a immunohistochemical evaluation of acetone-or formalin-fixed sections of frozen endometrial tissues, we found that irET was present in the glands and stromal cells of endometrium (J.R.Head, M.L. Casey and P.CMacDonald, unpublished data) . The levels of irET in frozen sections of endometrial tissue obtained on various days of the menstrual cycle vary considerably, with more intense staining in premenstrual endometrium. These findings are consistent with those of greater levels of preproET-1 mRNA in premenstrual/menstrual endometrium. Using formalin-fixed, paraffinembedded endometrial tissues, Salamonsen et al. (1992) and Cameron et aL (1992) also found that irET was localized principally in the glands. We have observed that the irET staining is reduced significantly in formalin-fixed, paraffin-embedded tissues compared with that in acetone-or formalinfixed frozen sections. These investigators also noted that irET is present in endometrial stromal cells.
We used endometrial stromal cells in culture as a model system to study the regulation of the levels of preproET-1 mRNA and irET production (Economos et al, 1992) . Immunoreactive ET-1 (viz. bigET-1 + ET-1) accumulates in the culture medium of these cells (Economos et al, 1992) .
ET-1 synthesis by endometrial stromal cells in response to TGF-fi TGF-Pl (1 ng/ml) acted to increase the level of preproET-1 mRNA in stromal cells and the amount of irET that accumulated in the medium by almost 2-fold (Economos et al, 1992) . These findings indicate that the preproET-1 gene, like PTH-rP, is also regulated in opposite fashions by progesterone (or MPA) and TGF-p. The mechanism(s) involved is not known at present.
ET receptors in human endometrial tissue Davenport et al. (1991) , O'Reilly et al (1992) and Kubota et al (1995) have presented evidence in support of the conclusion that ET A and ET B receptors are present in human endometrium. Messenger RNA for the ET A and ET B receptors has been detected by Northern analyses and reverse transcriptase/polymerase chain reactions, and the binding and functionality of the receptors have also been demonstrated. From an analysis of the levels or ET A and ET B receptor mRNA in endometrial tissue, it appears likely that the levels of these mRNA are regulated, either directly or indirectly, by sex steroid hormones. These findings are also supportive of the conclusion that ET may act in endometrium to modify the function of this tissue.
Enkephalinase
Neutral endopeptidase [membrane metalloendopeptidase; enkephalinase (EC 3.4.24.11)] is an extrinsic plasma membrane-bound enzyme that catalyses the degradation of ET-1 and several other small (M r <3000), potent, bioactive peptides (Sokolovsky et al, 1990; Vijayaraghavan et al., 1990) , viz. enkephalins, atrial natriuretic peptide, brain natriuretic peptide, substance P and chemotactic peptides. Enkephalinase is identical to common acute lymphoblastic leukaemia antigen (CALLA; Letarte et al., 1988) . This enzyme is present on many cells, but with high activity in only a few. Characteristically, enkephalinase activity is high in tissues in which the peptides it degrades are active (e.g. substance P in lung and intestine; atrial natriuretic peptide in kidney; enkephalins in brain). In keeping with this biological generalization, we find that the specific activity of enkephalinase in human endometrium is very high (Casey et al, 1991) . Enkephalinase (specific activity and immunoreactive protein) in endometrium is highest during the mid-luteal phase of the ovarian cycle (the expected time of implantation) and lowest just before and during menstruation (at the time of spiral artery vasoconstriction) (Casey etal, 1991; Head etal, 1993) . Endometrial enkephalinase is localized almost exclusively in the stromal cells (Head et al, 1993) , and enkephalinase is hormonally (progestin)-regulated in endometrial stromal cells in vitro (Casey et al, 1991; Head etal, 1993) .
Enkephalinase protein in endometrial tissue by
Western analysis To evaluate the relationship between the specific activity of enkephalinase and the level of enkephalinase protein in endometrial tissue during the luteal phase of the cycle, we conducted a sodium dodecyl sulphate-polyacrylamide gel electrophoresis and an immunoblot (Western) analysis of enkephalinase in endometrium obtained between cycle days 18 and 25 (Casey et al, 1991) . The apparent M, of ir-enkephalinase was -92 000, similar to that of rat kidney enkephalinase (Casey et al, 1991) . The amount of enkephalinase protein detected by a Western analysis corresponded with the specific activity of enkephalinase; in particular, there was a progressive increase in the amount of ir-enkephal-inase in endometrium from cycle days 18-21, a high level was maintained through day 23, and thereafter there was a decrease on days 24-25 (the last cycle day evaluated in this study).
Enkephalinase in endometrial stromal cells in
response to progestin treatment Based on the findings of enkephalinase in endometrial tissues, we surmized that progesterone acted, directly or indirectly, to increase enkephalinase gene expression. In exploring this proposition, we found that MPA alone or MPA + oestradiol effected dose-and time-dependent increases in the specific activity of enkephalinase (Casey et al, 1991) . MPA was more effective in increasing the specific activity of enkephalinase when oestradiol was present than when used alone. Again, we interpret this to reflect an increase in progesterone receptor number in response to oestradiol treatment The rate of increase in the specific activity of enkephalinase in endometrial stromal cells treated with MPA (20 nM) + oestradiol (10 nM) was similar to that observed in endometrial tissue in vivo during the early secretory phase of the endometrial cycle (Casey et al., 1991) . An increase in the specific activity of enkephalinase was effected by MPA at concentrations between 10~" and 10~7 M. Treatment of the cells with oestradiol alone did not affect the levels of enkephalinase mRNA or protein or the specific activity of enkephalinase (Casey et al, 1991) .
The levels of enkephalinase mRNA (evaluated by a Northern analysis) and enkephalinase protein (evaluated by a Western analysis) were also increased by the treatment of stromal cells with MPA alone or MPA + oestradiol. Two major species of enkephalinase mRNA (~3.7 and ~6.0 kb) and a number of other minor species (e.g. ~2.4 kb) were detected by a Northern analysis of total RNA from stromal cells (Casey et al, 1991) .
It is not known whether MPA acts to increase the steady state levels of enkephalinase mRNA by increasing enkephalinase gene transcription or by prolonging the half-life of enkephalinase mRNA. We suspect that MPA acts to increase enkephalinase gene transcription for several reason. Borson and Gruenert (1991) demonstrated that glucocorticosteroids act to increase the specific activity of enkephalinase in tracheal cells. Subsequently, we found that glucocorticosteroids act in other cells, e.g. human amnion cells, to increase the specific activity of enkephalinase and mRNA levels. As stated, progesterone and glucocorticosteroids can act via a common DNA response element (GRE/ PRE) (Strahle et al, 1989) to increase gene transcription. There are 16 consensus sequences for GRE/PRE (100% identity to the 10 bp consensus sequence) in the upstream region of the human enkephalinase gene.
Enkephalinase localization in endometrium by
immunohistochemical evaluation We evaluated (i) the cellular localization of enkephalinase in human endometrium and (ii) variations in the cellular distribution and density of ir-enkephalinase in endometrium during the menstrual cycle (Head et al, 1993) . Ir-enkephalinase is localized to the stromal cells. In keeping with the cyclical changes in enkephalinase specific activity in endometrial tissue, ir-enkephalinase was weak in proliferative phase tissues but very strong throughout the stromal compartment of the zona functionalis in early and mid-secretory phase tissues (Head et al., 1993) . During the late secretory and premenstrual phases of the cycle, differences in ir-enkephalinase density in various areas of the stroma were observed. Ir-enkephalinase in predecidualized stromal cells, which were immediately contiguous with the spiral arteries and beneath the surface epithelium, declined rapidly. In other non-predecidualized stromal cells, moderate irenkephalinase was retained until very late in the cycle, when ir-enkephalinase was very weak in most of the zona functionalis (Head et al, 1993) . The specific, rapid decline in enkephalinase in the predecidualized stromal cells that lie contiguous with the spiral arteries is dramatic and very important to various tenets of the hypothesis of this proposal (Head et al, 1993) .
Enkephalinase specific activity and protein and mRNA levels decline in the continued presence of progesterone There is a highly significant correlation between the plasma concentrations of progesterone and endometrial tissue enkephalinase specific activity and protein and mRNA levels. Moreover, MPA acts in stromal cells in culture to increase the specific activity of enkephalinase and protein and mRNA levels. Nonetheless, we concluded that factors other than progesterone withdrawal were involved in the rapid decline in endometrial enkephalinase specific activity during the last week of the cycle. Indeed, we were prompted to suggest, as have others, that progesterone withdrawal cannot be the sole physiological determinant in the induction of menstruation. There are three important findings that were suggestive of the important possibility that enkephalinase expression in the late luteal phase of the cycle is negatively regulated by some other agent.
(i) The late luteal phase decline in enkephalinase. The specific activity of enkephalinase begins to decline (in the mid-to late secretory phase) even though plasma progesterone concentrations are similar to those in the early to mid-secretory phase when the specific activity of enkephalinase is increasing. The decline in enkephalinase specific activity at the end of the secretory phase of infertile cycles was more rapid than expected in view of the concentration of plasma progesterone and the half-life of the enzyme. Even on day 23, when progesterone concentrations (~10 ng/ml) are still quite sufficient to evoke a maximal response, the specific activity of enkephalinase and protein in the endometrium are declining. Thus, it seems highly unlikely that the decline in enkephalinase specific activity, which commences on day -22, is singularly the consequence of falling concentrations of progesterone. Interestingly, predecidualization also begins on day 23 (of an idealized 28 day non-fertile cycle). Lorkowski et aL (1987) found that the half-life of enkephalinase in vivo was very long, i.e. ~3 days in human skin fibroblasts. We have found (by radiolabelling newly synthesized proteins of endometrial stromal cells with [
35 S]methionine and evaluating the disappearance of immuno-isolated radiolabelled enkephalinase) that the half-life of enkephalinase in endometrial stromal cells is alsõ 3 days. If this was an accurate estimate of the half-life of enkephalinase in vivo, then the steep decline in enkephalinase specific activity commencing on day ~23 could occur only if any new synthesis of enkephalinase ceased completely on days -21-22. Stated differently, the effect of progesterone to increase enkephalinase must have ceased completely on days -21-22, even though the plasma concentrations of progesterone are still more than adequate to effect a response via the progesterone receptor. As the stromal cells remain responsive to progesterone throughout the secretory phase of the cycle, this steep decline in enkephalinase specific activity suggests that a negative effector of enkephalinase is produced in late secretory endometrium.
(ii) Low enkephalinase specific activity in decidua. The specific activity of enkephalinase' in human decidua parietalis, at all stages of gestation evaluated.(12-40 weeks), is only 10-15% that in secretory endometrium (Casey et al., 1991) . Initially, this finding was surprising because the plasma concentrations of progesterone are much greater during human pregnancy than at any time during the secretory phase of the cycle. This finding also indicated that a negative effector of enkephalinase is produced in decidua that is able to 'overcome' the action of progesterone. This finding also suggested that a 'decidualizing' agent is the negative regulator of enkephalinase.
(iii) Specific decline in enkephalinase in predecidualized stromal cells, hi mid-to late secretory phase endometrium, the decrease in ir-enkephalinase (evaluated by a immunohistochemical analysis) is observed first in stromal cells undergoing predecidualization adjacent to the spiral arteries (Head etal., 1993) .
Each of these three observations is consistent with the possibility that an agent which promotes decidualization suppresses enkephalinase. We deduced that a negative effector of enkephalinase is produced in mid-to late secretory phase endometrium/decidua. It acts, even in the presence of progesterone, to suppress the specific activity of enkephalinase and protein levels. This deduction prompted us to conduct in-vitro studies in search of an agent that acts to inhibit enkephalinase synthesis. TGF-p was one of the first agents we tested as a naturally occurring antiprogestin MacDonald, 1993b, 1994) . We reasoned that TGF-P may serve such a role because TGF-P 1 mRNA and/or irTGF-pi have been identified in endometrial tissue during the mid-to late secretory phase and in decidua (Kauma et aL, 1990; Gold et aL, 1994 (Melampy et al, 1964; Kauma et al, 1990; Tamada et al, 1990; Graham et al, 1992; Lea et al, 1992; Manova etal, 1992) . We observed that the specific activity of enkephalinase declined with time in culture medium that contained fetal bovine serum (10%, v/v) (Casey et al, 1991) ; TGF-P is among the platelet-derived substances present in serum in large amounts.
Endometrial enkephalinase specific activity, mRNA and protein: TGF-0 inhibition Others have demonstrated that TGF-P inhibits the synthesis of mouse transin (stromelysin), also a metalloproteinase, by decreasing transin gene transcription (Machida et al, 1988; Kerr et al, 1990) . This inhibitory effect of TGF-P is dependent on the presence of a 10 bp TGF-P inhibitory element (TIE) in the promoter region of the transin gene (Kerr et al., 1990) . TIE have been identified in other genes that are inhibited by TGF-P (Matrisian etal., 1992) . The specific activity of enkephalinase declined in a time-and dose-dependent manner in endometrial stromal cells treated with TGF-P 1.
The specific activity of enkephalinase and the level of ir-enkephalinase protein (~92 kDa) in stromal cells treated for 72 h with serum-containing medium or with serum-free medium plus TGF-p was much lower than that in cells maintained in serum-free medium alone . After TGF-P 1 treatment of stromal cells for 4, 8, 16 or 48 h, the levels of enkephalinase mRNA were decreased compared with those in non-treated cells (Casey etal., 1993b) .
The extent of the reduction in enkephalinase mRNA (~50%) in endometrial stromal cells treated with TGF-P 1 is similar to that reported for the TTE-mediated decrease in transin mRNA levels. A number of TIE are present in the promoter/enhancer region of the enkephalinase gene, the functionality of which is under investigation. This is one mechanism by which TGF-p may effect a decrease in enkephalinase gene expression.
Enkephalinase in endometrial stromal cells: TGF-$1 acts as an antiprogestin to overcome the
effects of MPA TGF-P 1 acts in endometrial stromal cells not only to decrease the levels of enkephalinase mRNA, protein and specific activity, but also to prevent the stimulatory effect of MPA on enkephalinase. TGF-P 1 (1 ng/ml) acted to negate completely the stimulatory effects of MPA on enkephalinase specific activity, even when cells were pretreated for 4 days with MPA before TGF-P treatment was begun, and even in the continued presence of MPA MacDonald, 1994, 1996) . Marsh et al (1995) evaluated enkephalinase in the endometrial tissue of women with subdermally implanted levonorgestrel. Using immunohistochemical analyses, they found that the levels of immunoreactive enkephalinase were increased compared with those in proliferative phase endometrial tissue of ovulatory women not receiving progestin. These findings also suggested that ET may be important in modulating endometrial bleeding in women receiving levonorgestrel.
Enkephalinase in endometrial tissue of women receiving levonorgestrel
In the catarrhine primates, the mid-luteal to secretory phase of the ovarian/endometrial cycle is a critical branch point in the development and differentiation of the endometrium. This is the time of morphological and biochemical transition when (with blastocyst implantation) full decidualization commences or (in the absence of blastocyst implantation) the multiple changes in endometrium in preparation for menstruation (including predecidualization of the stromal cells) begin. We propose that TGF-P, produced and activated in the endometrium in situ, serve a pivotal role as autocrine/ paracrine-acting agents in denning the functional destiny of this tissue. In fact, TGF-P plus progesterone favours decidualization, but TGF-P also complements progesterone withdrawal to promote efficient endometrial shedding. In addition, TGF-P may serve a key role in the processes that lead to aberrant uterine bleeding. Therefore, we propose that TGF-P action is pivotal to the processes involved in either decidualization or menstruation. Even with non-fertile cycles, predecidualization of the stromal cells is prominent during the 5-6 days preceding menstruation, despite declining concentrations of plasma oestrogen and progesterone. We take the view, as did Markee (1940) , that selected changes in the stromal cells that accompany this predecidualization process are vitally important in the regulation of endometrial stromal cell vasoactive peptide formation/degradation and, thus, the modulation of endometrial vascular tone/flow.
TGF-f}, progesterone and decidualization
It has been clearly established that progesterone action is required for decidualization of the endometrium, but it is equally clear that progesterone alone cannot account for the complete decidualization found after trauma to the endometrium with pseudoprcgnancy in rodents or after implantation of the blastocyst in humans. TGF-P appears to be an ideal candidate as a co-decidualizing agent, and several important roles for TGF-P in decidualization have been proposed, including immunosuppression, stimulation of integrin and extracellular matrix formation, the regulation of trophoblast invasion, growth and differentiation, the modulation of endometrial enzyme activities, and regulation of the expression of selected genes. The theoretical actions of a co-decidualizing agent are consistent with the known actions of TGF-P in other cells or in endometrial stromal cells per se. TGF-P promotes the formation of extracellular matrix (Spom and Roberts, 1989) , and the process of decidualization is characterized by the formation of a distinctive pericellular 'membrane' around each decidual cell (Wewer et al., 1985) . TGF-P inhibits collagenase expression (Spom and Roberts, 1989) , as does progesterone (Marbaix et al., 1992) , and promotes the expression of tissue inhibitor of metalloproteinase-1 (Edwards et aL, 1987) and plasminogen activator inhibitor-1 (Hamilton et al., 1993; Schatz and Lockwood, 1993) in many tissues. TGF-P acts to inhibit epithelial cell growth, including that of the glandular epithelium of the endometrium (Marshburn et aL, 1994) , and regression of the glandular epithelium is a characteristic feature of decidual development in the human (Cunningham et aL, 1993) . TGF-P promotes the expression of tissue factor (Ranganathan et al., 1991) , as does progesterone , and tissue factor expression in decidua is very high . Tissue factor promotes clotting via the extrinsic pathway. Several investigators have identified TGF-P expression in decidual tissues and trophoblast of various species, including humans (Clark et al., 1988 (Clark et al., ,1990 Altman et al., 1990; Kauma et al., 1990; Tamada et al., 1990; Dungy et aL, 1991; Graham and Lala, 1991; Das et aL, 1992; Graham et aL, 1992; Manova etaL, 1992; Wilbanks and Streilein, 1992) . Tamada et al. (1990) and Das et al. (1992) evaluated the tissue sites of TGF-P expression and protein localization during the peri-implantation period in the mouse by immunolocalization of intra-and extracellular TGF-P, Northern analyses of tissue levels of TGF-P mRNA and in-situ hybridization. During the pre-implantation stage, TGF-P 1 mRNA and intracellular TGF-P 1 protein were co-localized in the endometrial epithelial cells. At this time, irTGF-pi was present only in the extracellular matrix of stroma, suggesting the accumulation of TGF-P 1 rather than synthesis in these cells. After implantation, irTGF-pi was intense in contiguous stroma both intra-and extracellularly. TGF-Pb synthesis/accumulation proceeded throughout the stroma in a wave-like fashion from the site of implantation. These findings are consistent with the cell-to-cell autoinduction of TGF-P 1 expression.
expression in the endometrium
The levels of TGF-P 1 mRNA and irTGF-Pl in human endometrium increase during the luteal phase (Kauma et al., 1990; Gold et aL, 1994; Marshburn et aL, 1994) . Thereafter, the expression of TGF-P 1 in decidua of early pregnancy is high, but the expression of TGF-P 1 in the late secretory phase of the non-fertile cycle is also high. It is probable that increased expression of TGF-P 1 in response to blastocyst implantation is promoted by a process of autoinduction in response to the secretion of TGF-P by the trophoblast (Dungy et aL, 1991) and in response to platelet-derived growth factor (PDGF) from maternal platelets at the site of implantation. The stimulus for increased TGF-P expression in late secretory endometrium, in the absence of implantation, is not known, but may be, in part, the result of endometrial vascular stasis. Hypoxia is known to increase TGF-p l as well as ET-1 and PDGF expression (Kourembanas et al., 1990 (Kourembanas et al., , 1991 Falanga et aL, 1991; Hashiguchi et al., 1991; L6pez-Farr6 et aL, 1991; Kourembanas, 1992; Wiebke et al., 1992) .
TGF-fi synthesis and activation of latent TGF-fi
TGF-pi, the prototype of the TGF-P family of multifunctional proteins, is derived from a 390 amino acid precursor that is cleaved to produce a 112 amino acid C-terminal peptide. The homodimer of this peptide (the active 25 kDa TGF-p1) is non-covalently associated with a dimer of the processed N-terminal pro-segment, called the latency-associated peptide (LAP). In some cells, LAP is, in turn, bound covalently to a third protein, i.e. latent TGF-P binding protein (LTBP). Therefore, the latent TGF-p complex, which is biologically inactive, comprises two or three separate proteins and is assembled before secretion from the cell. It is likely that active TGF-P (the 25 kDa homodimer) is not secreted from cells. Rather, in many cellular systems the crucial and limiting step in TGF-P action is the activation of latent TGF-P (for a review see Miyazono et al, 1993) . We suggest that the regulation of latent TGF-P formation and the activation of latent TGF-P in endometrium are of signal importance to the regulation of endometrial vascular tone/blood flow.
Plasmin-mediated activation of latent
Plasmin will act upon latent TGF-P to effect the release of active TGF-P from its non-covalent association with LAP. However, the concentration of plasmin in extracellular fluids is too low to catalyse this activation step. Therefore the activation of latent TGF-P is dependent on the creation of a high pericellular concentration of latent TGF-P in close proximity to a high pericellular concentration of plasmin. This is accomplished by the binding of substrate and enzyme to the plasma membrane of the same or contiguous cells. Placed in this context, the activation of latent TGF-P seems straightforward, but this is not the case. Pericellular plasmin-catalysed proteolysis is involved in a variety of vital cellular processes, including tissue growth, angiogenesis, cell migration, organ involution, metastasis and placentation, as well as the activation of latent TGF-p. Obviously, these sometimes disparate tissue/cellular processes do not and cannot proceed simultaneously. Plasmin-mediated degradation of the extracellular matrix is inconsistent with stromal cell decidualization and the formation of pericellular membranes. Rapid endometrial tissue growth and remodelling is quite a different process to endometrial hypoxia, necrosis and shedding. Clearly, multiple ancillary factors are involved in the expression of the membrane-bound plasmin enzyme activity. In the case of latent TGF-P activation, multiple sites of potential control are also operating and each is potentially liable to endocrine and paracrine control.
(i) Latent TGF-P does not bind to a TGF-P receptor, rather the latent TGF-P is bound via the LAP to the insulin-like growth factor (IGF-II) receptor, also known as the mannose-6-phosphate receptor. In addition, the latent TGF-P complex is bound to the cell surface in a second site, presumably by a specific receptor for LTBP, which has not been definitively identified (Flaumenhaft et al, 1993) . Binding of the latent TGF-p complex in this manner apparently concentrates the substrate in close proximity to cell membrane-associated plasmin. To concentrate plasmin in the pericellular space, however, two other plasma membrane receptors are required.
(ii) Plasminogen, the plasmin zymogen, is bound to the cell surface by a specific receptor that also binds plasmin. The plasminogen activator urokinase (uPA) is also bound to the cell surface by the uPA receptor (uPAR), a unique integral membrane protein that is anchored to the plasma membrane exclusively by a C-terminal glycosylphosphatidylinositol moiety. This receptor binds both uPA and its proenzyme (pro-uPA) with high affinity. Pro-uPA can be converted to uPA while bound to uPAR, and uPA, in turn, is active in its membrane-bound form. Therefore the activation of membrane-bound plasminogen to plasmin is accomplished by membrane-bound uPA acting on membrane-bound plasminogen. The plasmin remains associated with the plasminogen receptor in close proximity to bound latent TGF-p. In this manner, the concentration of plasmin is high, and active TGF-P is released from its non-covalent association with LAP.
(iii) Membrane-bound uPA can interact with plasminogen activator inhibitors-1 and -2 (PAI-1 and PAI-2). The uPAR does not internalize the uPA ligand, but the uPA-PAI complexes are internalized and degraded.
Therefore, uPA-catalysed cell surface plasmin-ogen activation requires the presence of uPAR but the absence of PAI-1 and PAI-2. The pattern of regulation of these three components, as well as the regulation of TGF-P gene expression, varies among cell types and in response to sex steroid hormones, growth factors and cytokines. This provides for a versatile but complex system for the regulation of cell surface plasminogen activation. Indeed, the system may be even more complex as selected growth factors may act to decrease the affinity of uPAR for uPA; yet another site of potential control involves the conversion of uPARbound pro-uPA to active two-chain uPA.
TGF-P synthesis and activation in response to steroid hormones A number of studies have been conducted to evaluate the role of steroid hormones and structurally related compounds in the expression and secretion of the various isoforms of TGF-p. Wakefield et al. (1990) observed that treatment of several types of cell with a variety of agents that act by way of the 'superfamily' of steroid receptors caused the increased accumulation of active TGF-P in a reasonably specific manner, i.e. cell specific and TGF-p isoform specific. For example, Glick et al. (1989) found that retinoic acid treatment of keratinocytes causes a specific increase in TGF-P2 mRNA levels and the formation of active TGF-P2 protein. Sex steroid hormones are also known to affect the levels of TGF-P mRNA and presumably the extent of latent TGF-P activation; indeed, there is evidence to suggest that some synthetic progestins act to modify the activation of latent TGF-P without affecting the level of TGF-P mRNA.
Oestrogen and TGF-P synthesis and activation
The effect of oestradiol treatment on the expression and formation of active TGF-P has been evaluated in a number of cell types in culture and in breast cancer cells in oestrogen-treated nude mice. Colletta et al (1991) found that there was no change in TGF-p secretion in response to oestrogen in either oestrogen receptor-positive (ER+) or oestrogen receptor-negative (ER-) breast cancer cells. Arrick et al (1990) found that oestrogen treatment of T47-D cells caused a decrease in TGF-P secretion and a reduction in the levels of TGF-P2 and TGF-P3 mRNA. Similarly, a decrease in TGF-P3 mRNA was observed in ZR-75-1 breast cancer cells with no change in mRNA for TGF-P in MCF-7 or MDA-MB-231 cells. In this same study, TGF-P 1 was not affected by oestrogen treatment in any cell type (Arrick et al, 1990) . Similarly, Jeng and Jordan (1991) found that with oestrogen treatment, the levels of TGF-p2 and TGF-P3 mRNA were decreased in MCF-7 cells, but the level of TGF-P 1 mRNA was not. Knabbe et al (1987) showed that oestrogen treatment negates the anti-oestrogen induction of TGF-P secretion in MCF-7 cells, and Kyprianou et al (1991) found that oestrogen treatment of castrate nude mice caused reduced levels of TGF-P 1 mRNA in implanted MCF-7 cells. Anzai et al. (1992) and Murphy et al. (1992) found that treatment of ER+ or ER-endometrial carcinoma cells caused little or no change in the levels of TGF-pi mRNA, and Colletta et al. (1990) determined that the treatment of fetal fibroblasts with oestrogen did not modify TGF-P secretion. In summary, oestrogen treatment of breast cancer cells, endometrial carcinoma cells and fetal fibroblasts in culture does not affect TGFpl expression but may reduce the levels of TGFp2 and TGF-p3 mRNA and secretion in oestrogenresponsive cells. Oestrogen treatment will nullify anti-oestrogen-induced increases in TGF-P 1 secretion and may reduce TGF-p 1 expression in responsive cells in vivo.
In contrast, Komm et al. (1988) found that after oestrogen treatment of osteoblast-like osteosarcoma cells, the level of TGF-P 1 mRNA was increased. Endometrial stromal cells respond to oestradiol by an increase in TGF-p3 mRNA (Arici et al, 1996) . Thus, there may be a fundamental difference in the response of ER+ epithelial and ER+ mesenchymal cells to oestrogen modulation of the TGF-P isoforms.
Synthetic progestins and TGF-P synthesis and activation It has been known for at least 30 years that the actions of progesterone and those of synthetic progestins are not identical. Indeed, the total biological effect of each synthetic progestin is potentially different from that of every other syndietic progestin. Some progestins act as oestrogen or as androgen surrogates, and yet others are potent antagonists of die mineralocorticosteroid receptor. 
TGF-0 modulation of the endometrlal ET-1-PTH-rP system
Differences between the actions of naturally occurring progesterone and those of various synthetic progestins to modulate the synthesis and activation of TGF-P may be extraordinarily important in determining the amount or timing of endometrial bleeding in women ingesting synthetic progestins. Some progestins, for example, stimulate the formation of TGF-p, whereas other synthetic progestins act to attenuate the formation of active TGF-p 1 . Gong et al (1991) found that MPA causes a small, somewhat inconsistent, decrease in TGF-P mRNA in endometrial cancer cells after long treatment times. Murphy et al. (1992) found that MPA caused a significant decrease in TGF-P mRNA levels in both HEC-50 and Ishikawa endometrial cancer cells. In this same study, treatment of these cells with 5a-dihydrotestosterone, dexamethasone, oestradiol, 4-hydroxytamoxifen, progesterone, RU486 and R-5020 did not cause a significant change in TGF-P 1 mRNA levels. Murphy and Dotzlaw (1989) found that treatment of T47-D breast cancer cells with MPA (10* 8 M) for 24 h reduced the level of TGF-P 1 mRNA to 10% that in untreated cells. In endometrial cancer cells, MPA causes a smaller, somewhat inconsistent, decrease in TGF-p mRNA (Gong et al, 1991) . Norethindrone (lCH-lO" 5 M) effects a marked decrease in TGF-P2 and TGF-P3 but no change in the levels of TGF-P 1 mRNA in MCF-7 breast cancer cells (Jeng and Jordan, 1991) . In this same study, R5020 and MPA did not affect the levels of TGF-P 1, TGF-P2 or TGF-P3 mRNA. Importantly, however, at low concentrations of norethindrone (10~1 0 -10" 8 M), the levels of TGF-p2 and TGF-p3 mRNA were increased. It is possible that some of the actions of norethindrone are mediated by the ER (Jeng and Jordan, 1991) . In another study, Colletta et al. (1991) demonstrated that the progestin 3-keto-desorgestrel did not cause an appreciable change in TGF-P secretion in T47-D cells; in these same cells, the synthetic progestin gestodene (17a-ethinyl-13P-ethyl-17P-hydroxy-4,15-oestradien-3-one) caused a 90-fold increase in the accumulation of active TGF-P1 and TGF-P2. This large increase in active TGF-P formation in response to gestodene is not the result of an increase in TGF-P 1 gene transcription (gestodene causes only a modest increase in the levels of TGF-p 1 mRNA); rather, gestodene acts by a post-transcriptional mechanism to increase the relative amount of active TGF-P 1, most likely by increasing the activation of latent TGF-P (Colletta et al., 1989 ) through a plasmindriven system. Iqbal and Colletta (1987) and Pollow et al. (1990) demonstrated that gestodene binds to the classic progesterone receptor in breast cancer tissues. These investigators, together with others, found that gestodene (in some breast cancer tissues and cell lines) also binds to a unique binding protein that binds oestradiol but at a different site (Iqbal and Valyani, 1988; Colletta et al, 1989) . It is by way of this unique protein (possibly an orphan receptor) that gestodene acts to increase the formation of active TGF-P (Colletta et al, 1991) . Gestodene did not cause an increase in TGFPl production in fetal lung or pituitary fibroblasts (Colletta et al, 1990) .
Regulation of TGF-P formation
Other investigators (Kauma et al, 1990; Gold etal., 1994; Selicketal, 1994) and we (Marshburn et al., 1994) have demonstrated that TGF-P mRNA are present in endometrial tissues. The level of TGF-P 1 mRNA in endometrium is low during the proliferative phase but increases during the secretory phase and remains high during menses. The levels of TGF-P3 mRNA are relatively constant throughout the cycle. Gold et al. (1994) found irTGF-pl, irTGF-P2 and irTGF-P3 in proliferative and secretory endometrium, with denser immunostaining in stroma than in glands. The antibodies used for these studies recognized latent and active TGF-p. We were unable to detect TGF-p2 mRNA in endometrium by a Northern analysis of total RNA (10 (xg); we have not yet attempted to detect this mRNA using more sensitive methods [e.g. poly(A) + mRNA and Northern analysis or ribonuclease protection assays].
TGF-P mRNA and immunorcactive protein in
separated endometrial cells In separated endometrial glands and stroma, TGFpl mRNA is present predominantly in stromal cells from secretory and menstrual phase endometria (Marshburn et al., 1994) . These findings are also consistent with those of Gold et aL (1994) in immunohistochemical analyses of TGF-P in endometrial tissues.
Regulation of TGF-01 and TGF-fi3 mRNA levels in endometrial stromal cells by PDGF, TGF-01
and cAMP TGF-Bl and TGF-B3 transcripts were detected, by a Northern analysis of total RNA, in endometrial stromal cells maintained in serum-containing medium. The level of TGF-B3 transcripts was distinctly less than that of TGF-Bl, but the levels of TGF-B3 mRNA increased in a time-dependent manner when the stromal cells were changed to serum-free medium. In endometrial stromal cells treated for 6 h with PDGF (1 and 10 ng/ml) or TGF-Bl (1 ng/ml), there was an increase in the steady-state level of TGF-Bl mRNA (Arici et al, 1996) . Many other cells (Van Obberghen-Schilling et al, 1988) respond to TGF-Bl by an autoinduction (viz. an increase in TGF-Bl mRNA). The increase in TGF-Bl mRNA levels in cells treated simultaneously with PDGF and TGF-Bl was more than additive, possibly reflecting distinct mechanisms of action of these agents to increase TGF-Bl mRNA levels. PDGF also caused an increase in TGF-B3 mRNA levels; in contrast, TGF-Bl treatment, in the absence or presence of PDGF, caused a marked decrease in TGF-B3 mRNA levels. The levels of TGF-B3 mRNA are increased in stromal cells by agents that activate adenylate cyclase or by cAMP surrogates (e.g. 8-bromocAMP, dibutyryl cAMP) (Arici et al, 1996) . Modulation of the levels ofTGF-fil and TGF-03 mRNA in endometrial stromal cells by oestradiol and MPA To evaluate the possibility that sex steroid hormones modulate TGF-Bl and TGF-B3 expression in endometrial stromal cells, some cells were pretreated for 48 h with oestradiol (50 nM), and then treated with MPA (1 nM) for 8 h with or without TGF-Bl (1 ng/ml). Oestradiol pretreatment enhanced the autoinduction of TGF-Bl mRNA (by TGF-Bl) (Arici et al, 1996) . Oestradiol treatment alone induced higher levels of TGF-B3 mRNA, and MPA induced a marked decrease in TGF-B3 mRNA levels. The inhibitory effect of MPA was more pronounced after oestradiol (50 nM, 48 h) pretreatment (Arici et al, 1996) . Latent TGF-fJ activation by endometrial stromal cells: uPAR It is clear that in many (perhaps most) systems, the activation of latent TGF-B is the crucial and limiting event in TGF-B action (for a review see Miyazono et al, 1993) . We have conducted preliminary studies to evaluate the potential for the regulation of latent TGF-B activation in endometrial stromal cells. We focused on the cellassociated plasmin-mediated activation of latent TGF-B. The activation of TGF-B by cell-associated plasmin is dependent on the presence of several cell surface proteins which serve to localize and concentrate the components of the system in close proximity. Specifically, latent TGF-B is bound by the LAP protein to the IGF-II receptor (mannose-6-phosphate receptor). Thus, it is localized and concentrated in a position that is accessible to the action of plasmin. Plasmin is formed from plasminogen by the action of urokinase, which is also concentrated at the cell surface by binding to the uPAR. The plasmin generated is also bound to the plasminogen receptor.
By immunohistochemical analyses of endometrial tissues from eight ovulatory women, we find very weak staining for uPAR during the proliferative phase, an increased intensity of staining by day 17, and very intense staining on days 23 and 24; there was very weak staining on day 4 (menses) and in endometrium from a postmenopausal women (J.R.Head, P.CMacDonald and M.L. Casey, unpublished data) . Thus, the cell-associated plasmin mechanism of TGF-B activation may be effected at the time of predecidualization of the endometrial stromal cells. By a Northern analysis, we find that uPAR mRNA is present in endometrial tissue, in freshly separated stromal cells and glands, and in endometrial stromal cells in monolayer culture (Le et al, 1994) . The levels of uPAR mRNA in endometrial stromal cells in culture are increased by agents that activate protein kinase C, e.g. tetradecanoyl phorbol acetate, or phosphatase inhibitors (Le et al, 1994) .
TGF-fi actions as an antiprogestin
We suggest that it is possible, even probable, that selected actions of progesterone, which are ideal for endometrial growth and development before blastocyst implantation, are not salutary to the function of the decidua of pregnancy. Therefore, it is reasonable to suggest that a substance that promotes decidualizan'on may complement some but selectively oppose other actions of progester-one. TGF-P is such a compound, acting in a genespecific manner to override selected actions of progesterone (and MPA). In addition, TGF-P acts to increase PTH-rP and ET-1 gene expression, which is suppressed by MPA, and to decrease enkephalinase gene expression (mRNA, protein, specific activity), which is increased by MPA . Perhaps TGF-P overrides those actions of progesterone that could impede the ideal development of the decidua. In the case of the administration of synthetic progestins, it is reasonable to expect that there may be alterations in the tissue levels of active TGF-P as a direct consequence of progestin-mediated effects on the expression/activation of latent TGF-P, which, in turn, may lead to anomalous tissue levels of ET-1 and/or PTH-rP, thereby contributing to aberrant endometrial bleeding.
Conclusion
We suggest that regulation of the expression and action of vasoactive proteins in the human endometrium may be a key event in modulating endometrial bleeding, both ovulatory bleeding and bleeding in response to the administration of synthetic progestins. Three points of summary are pertinent (i) The potential for the modulation of expression of genes for ET-1, PTH-rP and enkephalinase by progesterone and MPA has been demonstrated. It is likely that the tissue levels of these vasoactive proteins are modulated as a function of the ovarian cycle and in response to the administration of synthetic progestins that act through the progesterone receptor, (ii) Because of the central role of TGF-p in modulating the tissue levels of ET-1 and PTH-rP, both directly and indirectly through the inhibition of enkephalinase expression, we envisage the activation of latent TGF-p as a critical point in regulating this endometrial stromal cell vasoactive peptide system, (iii) Others have demonstrated clearly that the expression of TGF-P genes and (more importantly in our view) the activation of latent TGF-p in several steroid-responsive cell lines are modulated variously in response to synthetic progestins. Furthermore, the effects of different synthetic progestins on TGF-P expression and activation vary. This leads to the possibility that there are unique receptors (or other mechanisms) through which these agents act, as demonstrated for gestodene. But more than that, this result is a potential explanation for the finding of different responses to the administration of different synthetic progestins. Therefore, it is timely and essential, we suggest, that the regulation of TGF-P activation in endometrium by synthetic progestins be assessed in depth with vigour.
